SynAct Pharma AB (publ) has carried out a primary issuance of shares of approximately SEK 80 million in connection with the acquisition of TXP Pharma. 

SynAct Pharma conducts research and development in inflammatory diseases. The company has a platform technology based on a new class of drug candidates aimed at acute deterioration in chronic inflammatory diseases with the primary purpose of stimulating natural healing mechanisms.

ABG Sundal Collier and Van Lanschot Kempen acted as Joint Global Coordinators and Joint Bookrunners. Baker McKenzie acted as legal advisor to the banks with a capital markets team consisting of Joakim Falkner, Johanna Flink and Oscar Bang.
Explore Our Newsroom